ZA200903529B - Detection system and uses therefor - Google Patents

Detection system and uses therefor

Info

Publication number
ZA200903529B
ZA200903529B ZA200903529A ZA200903529A ZA200903529B ZA 200903529 B ZA200903529 B ZA 200903529B ZA 200903529 A ZA200903529 A ZA 200903529A ZA 200903529 A ZA200903529 A ZA 200903529A ZA 200903529 B ZA200903529 B ZA 200903529B
Authority
ZA
South Africa
Prior art keywords
detection system
uses therefor
therefor
detection
Prior art date
Application number
ZA200903529A
Other languages
English (en)
Inventor
Kevin Donald George Pfleger
Ruth Marie Seeber
Heng Boon See
Karin Ann Eidne
Original Assignee
Dimerix Bioscience Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006906292A external-priority patent/AU2006906292A0/en
Application filed by Dimerix Bioscience Pty Ltd filed Critical Dimerix Bioscience Pty Ltd
Publication of ZA200903529B publication Critical patent/ZA200903529B/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200903529A 2006-11-10 2009-05-21 Detection system and uses therefor ZA200903529B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2006906292A AU2006906292A0 (en) 2006-11-10 Detection System and Uses Therefor

Publications (1)

Publication Number Publication Date
ZA200903529B true ZA200903529B (en) 2010-03-31

Family

ID=39364112

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903529A ZA200903529B (en) 2006-11-10 2009-05-21 Detection system and uses therefor

Country Status (11)

Country Link
US (3) US20100234417A1 (zh)
EP (3) EP2080012B1 (zh)
JP (2) JP5313149B2 (zh)
KR (1) KR20090083925A (zh)
CN (1) CN101657715B (zh)
AU (2) AU2007317203B2 (zh)
CA (2) CA2669088C (zh)
DK (1) DK2080012T3 (zh)
IL (1) IL198639A (zh)
WO (2) WO2008055314A1 (zh)
ZA (1) ZA200903529B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
JP5352585B2 (ja) * 2007-07-13 2013-11-27 ネステク ソシエテ アノニム 抗体アレイを用いた肺癌治療のための薬剤選択
CA2704226A1 (en) * 2007-11-01 2009-05-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Cell-free methods for detecting protein-ligand interctions
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
CA2756743A1 (en) * 2009-03-27 2010-09-30 Dimerix Bioscience Pty Ltd. Novel receptor hetero-dimers/-oligomers
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
AU2012206945B2 (en) 2011-01-11 2015-02-19 Dimerix Bioscience Pty Ltd Combination therapy
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
JP6186575B2 (ja) 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
IE20120542A1 (en) * 2012-12-19 2014-07-02 Provost Fellows Foundation Scholars And Other Members Of Board Of The College Of The Holy And Undivi Novel TRH binding site in human CNS
MX2015012644A (es) * 2013-03-13 2016-06-21 Aerial Biopharma Llc Tratamiento de cataplejia.
CN114478773A (zh) 2015-01-09 2022-05-13 阿达尔塔有限公司 Cxcr4结合分子
KR102085554B1 (ko) * 2018-02-21 2020-03-06 영남대학교 산학협력단 사카로마이세스 세레비시애의 g-단백질 연결 수용체에 대한 알파 팩터의 친화도 측정방법
CN111089971B (zh) * 2019-12-11 2021-01-15 浙江大学 一种膜电位调控下的蛋白相互作用定量检测装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0318512B1 (en) * 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
AU1229000A (en) 1998-10-23 2000-05-15 Glaxo Group Limited Assays for ligands for nuclear receptors
AU2334801A (en) 1999-12-22 2001-07-03 Biosignal Packard Inc. A bioluminescence resonance energy transfer (bret) system with broad spectral resolution between donor and acceptor emission wavelengths and its use
US6893827B1 (en) 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
JP2005538683A (ja) * 2001-12-14 2005-12-22 ターガセプト，インコーポレイテッド 中枢神経系疾患の治療のための方法及び組成物
FR2836475B1 (fr) * 2002-02-26 2007-02-23 Aventis Pharma Sa Procede de detection de ligands du recepteur de la leptine
DE10218785A1 (de) 2002-04-26 2003-11-13 Infineon Technologies Ag Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
JP2004093527A (ja) * 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
DE602004031605D1 (de) * 2003-05-20 2011-04-14 Univ Glasgow Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen
CA2531698A1 (en) 2003-07-09 2005-01-27 Sentigen Biosciences, Inc. Method for assaying protein-protein interaction
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
US20080108128A1 (en) * 2003-11-19 2008-05-08 Eidne Karin A Resonance Energy Transfer Assay System for Multi-Component Detection
CN1627072A (zh) * 2003-12-11 2005-06-15 中国人民解放军军事医学科学院卫生学环境医学研究所 一种蛋白质芯片，其制备方法及用途

Also Published As

Publication number Publication date
JP2010509572A (ja) 2010-03-25
DK2080012T3 (da) 2013-06-17
US8568997B2 (en) 2013-10-29
EP2078037A4 (en) 2010-01-27
IL198639A (en) 2015-01-29
US20130065253A1 (en) 2013-03-14
US20100021457A1 (en) 2010-01-28
IL198639A0 (en) 2010-02-17
CA2669088A1 (en) 2008-05-15
CN101657715B (zh) 2012-07-25
JP2010510175A (ja) 2010-04-02
JP5313149B2 (ja) 2013-10-09
AU2007317203B2 (en) 2010-12-16
WO2008055314A1 (en) 2008-05-15
EP2605015A1 (en) 2013-06-19
EP2080012A1 (en) 2009-07-22
CN101657715A (zh) 2010-02-24
AU2007317203A1 (en) 2008-05-15
CA2669088C (en) 2016-04-05
CA2669185A1 (en) 2008-05-15
EP2080012A4 (en) 2010-01-27
US8283127B2 (en) 2012-10-09
EP2078037A1 (en) 2009-07-15
AU2007317204A1 (en) 2008-05-15
WO2008055313A1 (en) 2008-05-15
KR20090083925A (ko) 2009-08-04
US20100234417A1 (en) 2010-09-16
EP2080012B1 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
IL198639A0 (en) Detection system and uses therefor
EP2097740A4 (en) DETECTION SYSTEM
EP2082186B8 (en) Object position and orientation detection system
EP2235561B8 (en) Detection and ranging methods and systems
EP1974199A4 (en) DETECTION SYSTEM
GB2443055B (en) Fraud detection system
GB0621625D0 (en) Location detection
GB0622466D0 (en) An object detection system
EP2009464A4 (en) OBJECT DETECTION DEVICE
EP1967137A4 (en) POSITION RECOGNITION SYSTEM AND POSITION DETECTION METHOD
PL2210246T3 (pl) System wykrywania zbliżeniowego
EP2181640A4 (en) SYSTEM FOR DETECTING THE POSITION IN A SAMPLE AND METHOD FOR DETECTING THE POSITION IN A SAMPLE
GB2441854B (en) An object detection system and method
EP2215269A4 (en) CONSTRUCTION SYSTEM AND USES THEREFOR
GB0905005D0 (en) Advisory systems and methods
GB0603664D0 (en) Enzyme detection
EP1960989A4 (en) TOUCH PRIORITY SYSTEM
EP2076417A4 (en) ROAD EXIT DETECTION SYSTEM
EP1943127A4 (en) SYSTEM AND METHOD FOR OBJECT DETECTION
GB0603190D0 (en) Detection system
GB0510916D0 (en) Detection system
GB0621990D0 (en) Detection
GB0618669D0 (en) Detection
EP2020167A4 (en) GENERIC SYSTEMS AND METHODS FOR ANTI-ELECTROMAGNETIC SHIELDING
GB0624596D0 (en) Substance Detection System